Adult Dosing
Control severe nausea and vomiting
Note: Increase the dose in debilitated or emaciated patients except in elderly patients where the lowest dose is recommended. If WBC count decreases, stop the treatment and start the antibiotic or other suitable therapy.
Pediatric Dosing
- Safety and effectiveness in pediatric patients >2 years of age have not been established
- < 2 years contraindicated
[Outline]
See Supplemental Patient Information
- Geriatrics with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Not approved for the treatment of patients with dementia-related psychosis [US Black Box Warning]
- Extrapyramidal symptoms occurring secondary to prochlorperazine may be confused with the CNS signs of an undiagnosed primary disease responsible for the vomiting, e.g. Reye's Syndrome or other encephalopathy. Avoid use of prochlorperazine and other potential hepatotoxins in children and adolescents whose signs and symptoms suggest Reye's syndrome
- Tardive dyskinesia, a syndrome developed in patients treated with neuroleptic (anti-psychotic) drugs. It is observed highest in elderly, especially in elderly women. Tardive dyskinesia syndrome can be decreased in patients by giving relatively brief treatment periods at low doses
- Tardive dyskinesia may remit, partially or completely if neuroleptic treatment is withdrawn, neuroleptic (anti-psychotic) drugs itself mask or suppress the symptoms
- Chronic neuroleptic treatment should be given to patients who suffer from a chronic illness known to respond to neuroleptic drug and alternatively, equally effective, but potentially less harmful treatments are not available
- Patients with a history of long-term therapy with prochlorperazine and/or other neuroleptics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued
- Discontinue the drug if signs and symptoms of tardive dyskinesia appears during treatment
- Neuroleptic Malignant Syndrome (NMS) have been associated with antipsychotic drugs. Hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability are clinical symptoms of NMS
- NMS symptoms like serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS) must be identified during diagnosis
- Management of NMS should include discontinuation of antipsychotic drugs, intensive symptomatic treatment and medical monitoring and treatment of any concomitant serious medical problems
- Prochlorperazine or phenothiazine class of drug should be avoided in patients with bone marrow depression and hypersensitivity reaction (e.g., blood dyscrasias, jaundice)
- Masks the signs and symptoms of overdosage of other drugs; may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's Syndrome due to antiemetic action
- Aspiration of vomitus have occurred in post-surgical patients
- Children with acute illnesses (e.g., chicken pox, CNS infections, measles, gastroenteritis) or dehydration are more prone to neuromuscular reactions, particularly dystonias; closely supervise such patients during therapy
- Discontinue therapy at least 48 hrs before myelography, resume only after 24 hrs postprocedure. Avoid using for the control of nausea and vomiting occurring either prior to myelography with metrizamide, or post procedure
- Sudden appearance of sore throat or other signs of infection must be reported ; if counts indicate leukocyte depression, stop treatment and start antibiotic and other suitable therapy
Caution: Use cautiously in
- Dementia patient
- Seizure disorder
- Patient using CNS depressants
- Cardiovascular disease
- Use of oral anticoagulants
- Glaucoma
- History of drug induced leukopenia or neutropenia
- Leukopenia
- High environmental temperature
- Pediatric or adolescent patient
- Elderly patients
Supplemental Patient Information
- Advise patients to avoid engaging in activities requiring mental alertness such as operating a hazardous machinery or driving an automobile
Pregnancy Category:C
Breastfeeding: Based on minimal excretion of other phenothiazine derivatives, short term use for the treatment of nausea and vomiting poses little risk to breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT) last accessed 28 December 2010. As per manufacturer's data, prochlorperazine (phenothiazine) is excreted in breast milk of nursing mothers.
US Trade Name(s)
US Availability
prochlorperazine (generic)
Compro
Canadian Trade Name(s)
Canadian Availability
prochlorperazine (generic)
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
Stemetil
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Compro 25 MG SUPP [Box] (PADDOCK)
12 mg = $33.99
36 mg = $95.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
